VaingloryInvestor Posted - 5 days ago

$SLRN . Happy to initiate a position. We'll see where it goes.

IN0V8 Posted - 1 week ago

$SLRN H.C. Wainwright raises target price to $8 from $6

IN0V8 Posted - 1 week ago

$SLRN will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.

dogDazeSummer Posted - 10/30/24

$BIIB great beat but revenue off 2-3% stock should still rally Need to add a few strategic deals $IFRX $MLTX $SLRN

IN0V8 Posted - 1 month ago

$SLRN Opportunity Wells Fargo raises target price to $15 from $13

Thestocktraderhubzee Posted - 1 month ago

$SLRN Wells Fargo Maintains Overweight on Acelyrin, Raises Price Target to $15

Quantumup Posted - 1 month ago

H.C. Wainwright reiterated $MLTX Buy/$100, after conducting a survey of high-prescribing psoriatic arthritis (PSA) MD's to gain an understanding of how emerging IL-17 inhibitors could change existing Tx paradigms for patients with PsA. HCW🔑takeaways: $ucbjy $imvt $slrn $abbv nvs

madi1004 Posted - 1 month ago

$SLRN

EingeLTrade Posted - 1 month ago

$SLRN 👀 👀 👀 👀 👀 👀 👀 👀 👀 👀 👀 👀 👀 👀

Stocksrunner Posted - 1 month ago

📈 Comeback Kings! These stocks started the day in the red but rallied to close higher $WW $TGI $CURI $SLRN $CUE 🚀 Nice turnaround!

greenteaforus Posted - 1 month ago

$SLRN bullshit

G101SPM Posted - 09/23/24

#SHOWTIME ^^ Academy of Dermatology & Venereology Congress (September 24-25) Scheduled to appear: $ALMS, $CLDX, $MLTX, $ORKA, $SLRN ^^ Arrowhead Pharmaceuticals, Inc. R&D Webinar - Central Nervous System (September 24) Scheduled to appear: $ARWR ^^ Worthington Steel, Inc. Annual General Meeting (September 24) Scheduled to appear:$WS

PLATINUM_TRADES Posted - 2 months ago

$SLRN nice day yesterday I bet it jeeps going today and try to break $5.50 area🥊🥊🥊🥊

EingeLTrade Posted - 2 months ago

$SLRN on the radar 👀📡

G101SPM Posted - 2 months ago

$SLRN $5.41 +0.82. DAC (dollar average cost) (4) $4.925 last $4.30 (7.8.24). EXIT $15.00. UPDATE: Today announced that positive results from the company’s global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands.

ZohanCalls Posted - 2 months ago

$SLRN 100% of my alerts year to date have seen gains 🎁👂🏼it’s too simple

OpenOutcrier Posted - 2 months ago

$SLRN (+7.6% pre) ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - SI https://ooc.bz/l/42794

DonCorleone77 Posted - 2 months ago

$SLRN Acelyrin announces positive results from Phase 3 trial of izokibep ACELYRIN announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa, HS, patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Title: "Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Moderate-to-Severe Hidradenitis Suppurativa: Week 12 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study"

Stock_Titan Posted - 2 months ago

$SLRN ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 https://www.stocktitan.net/news/SLRN/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-6x6x8k2clxqr.html

Jenyber Posted - 2 months ago

$SLRN

deputy65 Posted - 2 months ago

$SLRN Got to get more eyes on this stock.

briefingcom Posted - 2 months ago

$SLRN: ACELYRIN announces positive proof-of-concept data from phase 1/2 clinical trial of lonigutamab as a subcutaneous treatment for thyroid eye disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240910070747SLRN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 2 months ago

$SLRN Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab ACELYRIN announced that data from its Phase 1/2 clinical trial of lonigutamab in thyroid eye disease will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery taking place from September 12-14, 2024 in Rotterdam, Netherlands. "The rapid suppression of IGF-1 receptor signaling observed with lonigutamab could potentially improve clinical outcomes for patients by achieving robust clinical responses with low drug exposures," said Shephard Mpofu, M.D., Chief Medical Officer of ACELYRIN. "Importantly, we believe these data are supportive of the potential for subcutaneously-delivered lonigutamab to provide deep and durable responses with convenient, self-administered dosing."

G101SPM Posted - 2 months ago

$SLRN $4.75 bid. DAC (dollar average cost) (4) $4.925 last $4.30 (7.8.24). EXIT $15.00. UPDATE: ACELYRIN announces positive proof-of-concept data from phase 1/2 clinical trial of lonigutamab as a subcutaneous treatment for thyroid eye disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery. Co announced that positive data from its Phase 1/2 clinical trial of lonigutamab (an anti-insulin-like growth factor 1 receptor, or IGF-1R) in thyroid eye disease (TED) will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) taking place from September 12-14, 2024 in Rotterdam, Netherlands. "The rapid suppression of IGF-1 receptor signaling observed with lonigutamab could potentially improve clinical outcomes for patients by achieving robust clinical responses with low drug exposures," said Shephard (Shep) Mpofu, M.D., Chief Medical Officer.

Stock_Titan Posted - 2 months ago

$SLRN ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery https://www.stocktitan.net/news/SLRN/acelyrin-inc-announces-positive-proof-of-concept-data-from-phase-1-2-mqaptxxb3d6j.html

StockInvest_us Posted - 08/30/24

Signal alert: $SLRN - Oversold Trend Short (Undervalued) https://stockinvest.us/l/y2qlnwSm6E

StockInvest_us Posted - 08/22/24

Signal alert: $SLRN - Oversold Trend Short (Undervalued) https://stockinvest.us/l/C0qmWqeHaE

ZohanCalls Posted - 3 months ago

$SLRN easy levels 👂🏼🎁

PerfectlyFine Posted - 3 months ago

$SLRN What is the reason for the pop today?

Powell6531 Posted - 3 months ago

$SLRN $SXTP $TGL $TTNP